Abstract: One-fifth (21%) had baseline resistance to at least one antiretroviral agent; the K103 N/S mutation was the most common mutation.
Method: The proportion of patients with M184 V/I, K103 N/S, and K65R mutations, as well as the presence of thymidine analogue mutations (TAMs) were also reported.
Result: Baseline resistance to at least one NNRTI was the most commonly observed resistance (with 12% of newly diagnosed asylum seekers exhibiting K103 N/S mutations; of these, 5/7 were from Latin America and 2/7 were from Africa), followed by NRTI resistance.
Discussion: In fact, among the seven newly diagnosed individuals with a K103 N/S mutation, three were wome
Survey of Pretreatment HIV Drug Resistance and Genetic Transmission Network Analysis Among HIV Patients in a High Drug-Use Area of Southwest China.
Result: Among the 119 NNRTI mutations identified, the most common mutation was K103N (45.5%), which can cause a high level of resistance to efavirenz (EFV) and nevirapine (NVP), the two ARV drugs that are the components of the WHO-recommended first-line regimens.
Result: Among them, the most common drug resistance mutation was K103N, and a total of 12 HIV infection patients contained this drug resistance mutation and were distributed in 10 transmission clusters.
Discussion:
Discussion: EFV and NVP, which are both NNRTIs, had the highest drug resistance rate in this study which was mainly caused by K103N, V179D, V106M and E138G/Q mutations.
Analysis of HIV-1 diversity, primary drug resistance and transmission networks in Croatia.
Result: Forward transmission of SDRMs throughout the period 2014-2017 was determined in several TCs: (1) T215S (n = 20) and its sub-cluster T215S + L210W (n = 9) (2), K101E (n = 14) and (3) V32I + I47V + T215D/E + L100I + K103N (n = 8).
Result: Resistance to NNRTIs was determined in 27/403 (6.7%) cases, with mutations K101E (3.7%), K103N (2.5%) and L100I (1.9%) most frequently observed.
Result: Some of these sequences carrying SDRMs: T69D, G190E, K219Q and
Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon.
Abstract: M184V (8.4%, 20/239) and K103N (5.4%, 13/239) were the most prevalent mutations.
Result: M184V (8.4%, 20/239) and K103N (5.4%, 13/239) were the most frequent NRTI- and NNRTI-associated mutations respectively.
Result: The most common patterns among ART-experience patients were K103N only or in combination with P225H or V106A (9.8%, 4/41), Y181C only or in combin
Table: K103N
Discussion: K103N also was the most prevalent NNRTI mutation and is responsible for cross-resistance in this drug class.
HIV Drug Resistance among Patients Failing Therapy at a Tertiary Center in Oman: A Case Record Review.
Abstract: The phylogenetic analyses of the amplified region of pol gene indicated that all of the 15 HIV-1-infected pediatric patients were infected by CRF35_AD, and a total of 13.3% (2/15) of these children were infected with HIV-1 variants with SDRMs (one child harbored two related SDRMs [D67N, V179F], and another child had three related SDRMs [M184V, T215F, and K103N]), according to the last algorithm of the WHO.
HIV Drug Resistance after Failure of 6 Month First-line Therapy in a Hospital: A Case Series.
Abstract: The common NRTI mutations were M184VI and K65R, while NNRTI mutations were Y181CFGVY, K103N, A98AG, E138GQ and G190AGS.
HIV-1 subtype diversity, drug resistance, and genetic transmission networks in men who have sex with men with virologic failure in antiretroviral therapy in Sichuan, China, 2011 to 2017.
Abstract: The most common drug resistance-associated mutations in protease inhibitors (PIs), NRTIs and NNRTIs were K20I/R, M184V/I and K103N/KN, respectively.
Result: K103N/KN (155/372,
Discussion: We observed that K103N/KN, V106M/MA/MV, G190A/AG/S, and Y188L/C are the major NNRTI-related mutations in China and other countries, which may be the result of the wide-spread use of NNRTIs.
Molecular Genetics and the Incidence of Transmitted Drug Resistance Among Pre-Treatment HIV-1 Infected Patients in the Eastern Cape, South Africa.